Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Beryl Drugs Ltd. significantly lags behind its peers in terms of growth, profitability, and valuation metrics. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit strong profitability and growth, while Beryl shows no positive growth metrics and a high PE ratio compared to its peers. This positions Beryl as an underperformer in the Pharmaceuticals & Drugs sector.
Strong revenue growth (13.28% YoY) and solid profitability with a PE of 23.73 and ROE of 16.63%.
Offers a balanced combination of growth (16.54% YoY) and low valuation metrics with a PE of 15.50.